[go: up one dir, main page]

ES2069995T5 - Mejoras en composiciones farmaceuticas. - Google Patents

Mejoras en composiciones farmaceuticas.

Info

Publication number
ES2069995T5
ES2069995T5 ES92908795T ES92908795T ES2069995T5 ES 2069995 T5 ES2069995 T5 ES 2069995T5 ES 92908795 T ES92908795 T ES 92908795T ES 92908795 T ES92908795 T ES 92908795T ES 2069995 T5 ES2069995 T5 ES 2069995T5
Authority
ES
Spain
Prior art keywords
peso
pharmaceutical compositions
particles
aize
nanometers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92908795T
Other languages
English (en)
Other versions
ES2069995T3 (es
Inventor
Peter Gassmann
Heinz Sucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27202407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2069995(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2069995T3 publication Critical patent/ES2069995T3/es
Publication of ES2069995T5 publication Critical patent/ES2069995T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Colloid Chemistry (AREA)

Abstract

PARTICULAS DE UNA SUSTANCIA, SUSTANCIALMENTE INSOLUBLE EN AGUA, BIOLOGICAMENTE ACTIVA, CARGADA CON UN ESTER DE GLICEROL CARGADO COMO UN ESTABILIZADOR ELECTROSTATICO, LA CUAL IMPARTE A LAS PARTICULAS UN POTENCIAL ZETA Y QUE TIENE UNA PROPORCION SUSTANCIA ACTIVA: PESO DE ESTABILIZADOR DE 1:1 A 400:1 Y UN DIAMETRO MEDIO DE PARTICULA DE 1 NANOMETRO A 10 NANOMETROS SE USAN EN SISTEMAS DE LIBERACION.
ES92908795T 1991-04-19 1992-04-16 Mejoras en composiciones farmaceuticas. Expired - Lifetime ES2069995T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4112854 1991-04-19
DE4113016 1991-04-20
DE4113343 1991-04-24
PCT/EP1992/000862 WO1992018105A1 (en) 1991-04-19 1992-04-16 Improvements in pharmaceutical compositions

Publications (2)

Publication Number Publication Date
ES2069995T3 ES2069995T3 (es) 1995-05-16
ES2069995T5 true ES2069995T5 (es) 2000-11-16

Family

ID=27202407

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92908795T Expired - Lifetime ES2069995T5 (es) 1991-04-19 1992-04-16 Mejoras en composiciones farmaceuticas.

Country Status (16)

Country Link
EP (1) EP0580690B2 (es)
JP (1) JP3695754B2 (es)
AT (1) AT410896B (es)
AU (1) AU1577992A (es)
CA (1) CA2108018C (es)
DE (1) DE4291156T1 (es)
ES (1) ES2069995T5 (es)
FR (1) FR2675382B1 (es)
GB (1) GB2269536B (es)
IE (1) IE921230A1 (es)
IL (1) IL101635A0 (es)
IT (1) IT1254323B (es)
MX (1) MX9201782A (es)
NO (1) NO933695D0 (es)
WO (1) WO1992018105A1 (es)
ZA (1) ZA922834B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
EP2275089A1 (en) * 1993-11-19 2011-01-19 Alkermes Controlled Therapeutics, Inc. Preparation of biodegradable microparticles containing a biologically active agent
EP0810853B1 (en) 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols containing nanoparticle dispersions
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
TW497974B (en) * 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
DE69929959T2 (de) 1998-03-30 2006-11-02 Jagotec Ag Zubereitungen enthaltend mikropartikel von wasserunlöslichen substanzen, sowie verfahren zu deren herstellung
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DE19821951A1 (de) * 1998-05-15 1999-11-18 Basf Ag Cyclosporin-Zubereitungen
KR100635456B1 (ko) 1998-05-29 2006-10-18 스키에파마 캐나다 인코포레이티드 열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법
HK1042856B (zh) 1998-11-20 2007-07-27 Skyepharma Canada Inc. 可分散的磷脂稳定的微粒
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
EP1959966B1 (en) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
CA2669392C (en) 2006-11-17 2016-05-10 Abbott Gmbh & Co. Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
WO2008066899A2 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
HU230862B1 (hu) 2008-04-28 2018-10-29 DARHOLDING Vagyonkezelő Kft Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
GB201410869D0 (en) * 2014-06-18 2014-07-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontal disease
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
CA3001722A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
US20180042903A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
IL293525A (en) 2019-12-06 2022-08-01 Marinus Pharmaceuticals Inc Ganaxolone for use in the treatment of multiple sclerosis complex
JP2022031250A (ja) * 2020-08-07 2022-02-18 国立大学法人信州大学 リポソームおよびその製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1532993A (en) * 1975-03-07 1978-11-22 Beecham Group Ltd Injectable antibiotic compositions
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US5002940A (en) * 1984-11-06 1991-03-26 Ciba-Geigy Corporation Solid drug formulations and stable suspensions
CH673395A5 (es) * 1987-01-30 1990-03-15 Ciba Geigy Ag
CA1323306C (en) * 1987-03-05 1993-10-19 Mircea C. Popescu Pharmacological agent-lipid solution preparation
US4963362A (en) † 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
GB2230440B (en) † 1989-02-09 1993-05-19 Sandoz Ltd Novel cyclosporin galenic forms

Also Published As

Publication number Publication date
ATA901092A (de) 2003-01-15
CA2108018C (en) 2003-04-15
MX9201782A (es) 1992-10-01
ZA922834B (en) 1993-10-18
WO1992018105A1 (en) 1992-10-29
GB2269536A (en) 1994-02-16
ITRM920281A1 (it) 1993-10-16
AT410896B (de) 2003-08-25
FR2675382B1 (fr) 1995-05-12
EP0580690B2 (en) 2000-09-13
AU1577992A (en) 1992-11-17
CA2108018A1 (en) 1992-10-20
EP0580690B1 (en) 1995-03-15
DE4291156T1 (de) 1994-10-20
GB2269536B (en) 1995-05-10
ES2069995T3 (es) 1995-05-16
JP3695754B2 (ja) 2005-09-14
IT1254323B (it) 1995-09-14
FR2675382A1 (fr) 1992-10-23
JPH06506926A (ja) 1994-08-04
EP0580690A1 (en) 1994-02-02
IL101635A0 (en) 1992-12-30
GB9319585D0 (en) 1993-12-15
ITRM920281A0 (it) 1992-04-16
NO933695D0 (no) 1993-10-14
IE921230A1 (en) 1992-10-21

Similar Documents

Publication Publication Date Title
ES2069995T5 (es) Mejoras en composiciones farmaceuticas.
CO4920214A1 (es) Composiciones que contienen tetrahidrolipstatina
CY1110949T1 (el) Σταθεροποιημενες με πηκτωμα συνθεσεις νανοσωματιδιακων δραστικων παραγοντων
ATE217523T1 (de) Loteprednoletabonat-suspension
SE8705043D0 (sv) Hydrosols of pharmacologically active agents and their pharmaceutical compositions comprising them
DE69835162D1 (de) Geschmacksmaskierte pharmazeutische zusammensetzungen
ATE152620T1 (de) Pharmazeutischer träger
ATE55243T1 (de) Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung.
DE69325796D1 (de) Pharmazeutische oder kosmetische öl-in-wasser emulsion mit positivgeladenen teilchen
DE69516960D1 (de) Sulfatierte hyaluronsäure mit 0.5 bis weniger als 2 sulfate gruppen pro einheit
SE8900542L (sv) Administreringssystem foer farmakologiska medel
DE69812343D1 (de) Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff
KR880004804A (ko) 분무건조 아세트 아미노펜
ATE381317T1 (de) Nanopartikuläre zusammensetzungen in form festen darreichungen
AR248164A1 (es) Proceso para fabricar granulos detergentes revestidos por cargas electrostaticas.
MY124599A (en) Oral suspension of pharmaceutical substance
CO4980893A1 (es) Granulos que comprenden clavulanato y excipientes
CO5160317A1 (es) Microgranulos de sulfato de morfina, procedimiento para su preparacion y composicion que los contiene
SE0203687D0 (sv) Pharmaceutical Porous Particles
EA200300110A1 (ru) Композиция элетриптана в виде частиц
CO4410174A1 (es) Preparaciones farmaceuticas de cefixima
CO4970742A1 (es) Suspension farmaceutica que comprende hemihidrato de nevipa- rina
FR2797446B1 (fr) Derives de phenanthroline-7-ones et leurs applications en therapeutique
Smulders et al. Nano-titanium dioxide modulates the dermal sensitization potency of DNCB
AR019776A1 (es) Implante aloplastico de microparticulas para medicina estetica y aplicacion del mismo

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 580690

Country of ref document: ES